Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials

English version České info

Background:
Calcimimetic agents lower serum parathyroid hormone levels in people with chronic kidney disease (CKD), but treatment effects on patient-relevant outcomes are uncertain. We conducted a systematic review and meta-analysis to summarize the benefits and harms of calcimimetic therapy in adults with CKD and used cumulative meta-analysis to identify how evidence for calcimimetic treatment has developed in this clinical setting.

Methods and Findings:
Cochrane and Embase databases (through February 7, 2013) were electronically searched to identify randomized trials evaluating effects of calcimimetic therapy on mortality and adverse events in adults with CKD. Two independent reviewers identified trials, extracted data, and assessed risk of bias.

Eighteen trials comprising 7,446 participants compared cinacalcet plus conventional therapy with placebo or no treatment plus conventional therapy in adults with CKD. In moderate- to high-quality evidence (based on Grading of Recommendations Assessment, Development, and Evaluation criteria) in adults with CKD stage 5D (dialysis), cinacalcet had little or no effect on all-cause mortality (relative risk, 0.97 [95% confidence interval, 0.89–1.05]), had imprecise effect on cardiovascular mortality (0.67 [0.16–2.87]), and prevented parathyroidectomy (0.49 [0.40–0.59]) and hypercalcemia (0.23 [0.05–0.97]), but increased hypocalcemia (6.98 [5.10–9.53]), nausea (2.02 [1.45–2.81]), and vomiting (1.97 [1.73–2.24]). Data for clinical outcomes were sparse in adults with CKD stages 3–5. On average, treating 1,000 people with CKD stage 5D for 1 y had no effect on survival and prevented about three patients from experiencing parathyroidectomy, whilst 60 experienced hypocalcemia and 150 experienced nausea. Analyses were limited by insufficient data in CKD stages 3–5 and kidney transplant recipients.

Conclusions:
Cinacalcet reduces the need for parathyroidectomy in patients with CKD stage 5D, but does not appear to improve all-cause or cardiovascular mortality. Additional trials in CKD stage 5D are unlikely to change our confidence in the treatment effects of cinacalcet in this population.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials. PLoS Med 10(4): e32767. doi:10.1371/journal.pmed.1001436
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001436

Souhrn

Zdroje

1. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1): S1–S266.

2. GoAS, ChertowGM, FanD, McCullochCE, HsuCY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.

3. HemmelgarnBR, MannsBJ, LloydA, JamesMT, KlarenbachS, et al. (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303: 423–429.

4. DalrympleLS, GoAS (2008) Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1487–1493.

5. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases (2012) 2012 USRDS annual data report: atlas of chronic kidney disease in the United States. Bethesda (Maryland): National Institutes of Health.

6. EknoyanG, BeckGJ, CheungAK, DaugirdasJT, GreeneT, et al. (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019.

7. FellstromBC, JardineAG, SchmiederRE, HoldaasH, BannisterK, et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407.

8. PalmerSC, Di MiccoL, RazavianM, CraigJC, PerkovicV, et al. (2012) Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 156: 445–459.

9. PhrommintikulA, HaasSJ, ElsikM, KrumH (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381–388.

10. WannerC, KraneV, MarzW, OlschewskiM, MannJF, et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248.

11. Kidney Disease: Improving Global Outcomes (2012) KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Available: http://www.kdigo.org/guidelines/mbd/index.html. Accessed 14 November 2012.

12. NavaneethanSD, PalmerSC, VecchioM, CraigJC, ElderGJ, et al. (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011: CD006023.

13. PalmerSC, McGregorDO, MacaskillP, CraigJC, ElderGJ, et al. (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840–853.

14. US Food and Drug Administration (2011) Sensipar (cinacalcet) tablets: prescribing information. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021688s017lbl.pdf. Accessed 14 November 2012.

15. MizobuchiM, OgataH, HatamuraI, SajiF, KoiwaF, et al. (2007) Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 362: 11–16.

16. MentaverriR, YanoS, ChattopadhyayN, PetitL, KiforO, et al. (2006) The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J 20: 2562–2564.

17. BlockGA, ZaunD, SmitsG, PerskyM, BrillhartS, et al. (2010) Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78: 578–589.

18. CunninghamJ, DaneseM, OlsonK, KlassenP, ChertowGM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793–1800.

19. GoodmanWG, FrazaoJM, GoodkinDA, TurnerSA, LiuW, et al. (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58: 436–445.

20. GoodmanWG, HladikGA, TurnerSA, BlaisdellPW, GoodkinDA, et al. (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017–1024.

21. StrippoliGF, TongA, PalmerSC, ElderG, CraigJC (2006) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006: CD006254.

22. National Health Service, The Information Centre for Health and Social Care (2012) Hospital prescribing, England: 2011. Available: https://catalogue.ic.nhs.uk/publications/prescribing/primary/hosp-pres-eng-2011/hosp-pres-eng-2011-rep.pdf. Accessed 6 February 2013.

23. The EVOLVE Trial Investigators (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482–2494.

24. Higgins JPT, Green S, editors (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0. Oxford: The Cochrane Collaboration. Available: http://handbook.cochrane.org/. Accessed 28 March 2013.

25. ThorlundK, ImbergerG, JohnstonBC, WalshM, AwadT, et al. (2012) Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE 7: e39471 doi:10.1371/journal.pone.0039471.

26. HarbordRM, EggerM, SterneJA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25: 3443–3457.

27. DuvalS, TweedieR (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455–463.

28. GuyattGH, OxmanAD, VistGE, KunzR, Falck-YtterY, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924–926.

29. WeinerDE, TabatabaiS, TighiouartH, ElsayedE, BansalN, et al. (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48: 392–401.

30. KestenbaumB, SeligerSL, GillenDL, WasseH, YoungB, et al. (2004) Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int 65: 282–288.

31. LindbergJS, MoeSM, GoodmanWG, CoburnJW, SpragueSM, et al. (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248–254.

32. QuarlesLD, SherrardDJ, AdlerS, RosanskySJ, McCaryLC, et al. (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575–583.

33. BlockGA, MartinKJ, de FranciscoAL, TurnerSA, AvramMM, et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525.

34. HarrisRZ, PadhiD, MarburyTC, NovelckRJ, SalfiM, et al. (2004) Pharmacokinetics, pharmacodynamics and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44: 1070–1076.

35. CharytanC, CoburnJW, ChoncholM, HermanJ, LienYH, et al. (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58–67.

36. LindbergJS, CulletonB, WongG, BorahMF, ClarkRV, et al. (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800–807.

37. FishbaneS, ShapiroWB, CorryDB, VicksSL, RoppoloM, et al. (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3: 1718–1725.

38. AkibaT, AkizawaT, TsukamotoY, UchidaE, IwasakiM, et al. (2008) Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 12: 117–125.

39. FukagawaM, YumitaS, AkizawaT, UchidaE, TsukamotoY, et al. (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23: 328–335.

40. MallucheHH, Monier-FaugereMC, WangG, FrazaOJ, CharytanC, et al. (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269–278.

41. MessaP, MacarioF, YaqoobM, BoumanK, BraunJ, et al. (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36–45.

42. ChoncholM, LocatelliF, AbboudHE, CharytanC, de FranciscoAL, et al. (2009) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53: 197–207.

43. RaggiP, ChertowGM, TorresPU, CsikyB, NasoA, et al. (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26: 1327–1339.

44. El ShafeyEM, AlsahowAE, AlsaranK, SabryAA, AtiaM (2011) Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 15: 547–555.

45. KettelerM, MartinKJ, WolfM, AmdahlM, CozzolinoM, et al. (2012) Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 27: 3270–3278.

46. National Health Service National Institute for Health and Clinical Excellence (2011) TA117 hyperparathyroidism—cinacalcet: guidance. Available: http://guidance.nice.org.uk/TA117/Guidance/pdf/English. Accessed 14 November 2012.

47. KovesdyCP, AhmadzadehS, AndersonJE, Kalantar-ZadehK (2008) Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168: 397–403.